EM Vivas · Snake envenomation
Snake envenomation — antivenom and VICC viva
Clinical viva on ANZ elapid envenomation, VICC vs DIC, modern antivenom dosing, and ASP evidence.
On this page
Study tools
Target exams
Interpretation
Reveal interpretationShowHide
Syndrome. Laboratory pattern of extreme consumptive coagulopathy with preserved platelets is VICC, not DIC. Brown snake is the classic isolated-VICC culprit; tiger/taipan add neurotoxicity and myolysis — examine for ptosis and track CK.[1]
First aid. Pressure immobilisation bandage of the entire limb + immobilisation. Leave it on until antivenom ready. SVDK guides monovalent choice but clinical syndrome and geography can override. [1]
Antivenom. Indicated for any systemic envenomation. Unidentified snake → polyvalent; identified group → monovalent (brown 1–2 vials; tiger 2–4 vials commonly). IV diluted infusion; adrenaline 0.25 mg subcutaneous premedication (randomised-trial regimen; severe reactions reduced 43 per cent at 1 hour); monitored area.[1][2][3]
Blood products. Only if bleeding, after antivenom. Factors first are re-consumed. [1]
Neurotoxic patterns. Presynaptic (tiger/taipan) paralysis is poorly reversible — intubate early for bulbar failure. Death adder postsynaptic paralysis may respond to antivenom ± neostigmine bridge. [1][4]
References4ShowHide
- [1]Johnston CI, Ryan NM, Page CB, et al. The Australian Snakebite Project, 2005-2015 (ASP-20). Med J Aust, 2017.PMID 28764620
- [2]Isbister GK, Brown SG, MacDonald E, et al. Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis. Med J Aust, 2008.PMID 18429716
- [3]de Silva HA, Pathmeswaran A, Ranasinha CD, et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS Med, 2011.PMID 21572992
- [4]Johnston CI, Ryan NM, O'Leary MA, et al. Australian taipan (Oxyuranus spp.) envenoming: clinical effects and potential benefits of early antivenom therapy - Australian Snakebite Project (ASP-25). Clin Toxicol (Phila), 2017.PMID 27903075